Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KN003
- Development stage
- Preclinical
- Lead developer
- Suzhou Alphamab
01
Overview
KN003 is an early-stage innovative biologic drug candidate under development by Suzhou Alphamab. It is being investigated for the treatment of infectious diseases. Detailed pharmacological data, including its specific molecular target, mechanism of action, and clinical development phase, have not been publicly disclosed.
Beyond the preview
Go deeper on KN003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KN003.